$3 Billion in Milestones Disappear: The 2025 Shock That Forced GSK’s Hand
When the October 2025 news broke, GSK taking a $3 billion write-down on immuno-oncology (IO) milestone obligations, both the City and the Street caught the signal. A clear return to the drawing board for late-stage bets. The collapse of GSK’s pivotal ZY-1677 trial in advanced lung cancer wasn’t just about missing secondary endpoints, not this time. This one untangled an entire network of co-development deals, all built around back-loaded, outsized biobucks and a tangle of future royalties. GSK’s immuno-oncology ambitions, propped up by licensing agreements touting up to $600 million in milestones for each asset, suddenly looked not only expensive, but completely out of step with clinical realities.
That $3 billion write-down isn’t merely accounting. It’s the inevitable consequence of the high-wire act big pharma has played in IO since the Opdivo-Keytruda duopoly dominated the late 2010s. GSK’s expansive IO partnerships, from TCR bispecifics to small-molecule checkpoint agonists, appeared diversified on paper. But in truth, the portfolio hinged on a handful of big, binary readouts. The events of 2025 hammered home an uncomfortable point: the old playbook of big upfront payments plus distant, headline-grabbing milestones no longer matches how risk actually plays out in IO. GSK needed a new approach to share risk, align incentives, and salvage value from a battered pipeline.
Ripping Up the Rulebook: GSK’s Partnership Restructurings in 2026
By February 2026, GSK had torn up its playbook with five major partnership restructurings. Adaptimmune, Tizona, two unnamed Asian biotechs, the list reads like a who’s who of its former IO ambitions. Gone: the $250 million milestone cliffs tied to FDA approvals. In their place, dynamic profit shares and asset carve-outs that trade regional rights for flexibility. The first quarter 2026 filings are blunt: $1.2 billion in contingent liabilities wiped away, replaced by a tighter, capped royalty structure, 12 percent at the ceiling, not the wild 20 percent-plus once on offer. R&D costs are now split in more predictable, less painful ways.
Inside the company, the shakeup has forced a rethink of how GSK’s BD&L teams select assets. 2026 priorities aren’t about splashing into every blue-sky indication, but about stepwise, de-risked development. In the revised Adaptimmune deal, GSK paid a $40 million reset for a global option on a next-gen TCR platform, but only doles out future payments if clinical proof-of-concept is reached. No more all-or-nothing bets on regulatory finish lines. With Tizona’s anti-CD39, GSK dropped US co-promotion in favor of ex-US rights, instantly chopping opex and letting Tizona take the brunt of the US launch challenge. An open question: does this mean biotech partners will actually get more control? Some seem optimistic, others suspicious.
The result? Smaller upfront payments. Lower “theoretical” upside for all parties. But a structure that’s less likely to implode when trials go south. No more window dressing, boardrooms simply won’t entertain old milestone deals, and partners understand that stacking up “phantom” future payments doesn’t help when approvals never arrive. There’s a new realism in dealmaking. Want to see how this shift is spreading across the sector? RxInfo.ai keeps a running tally.
Pared Down, Pushed Harder: GSK’s New IO Pipeline Priorities
In 2025, GSK ran a dozen partnered IO programs across eight mechanisms. Fast forward: that portfolio is now pruned to five core bets. Only two or three expected to reach pivotal studies in the next 24 months, according to internal presentations. The new philosophy: cull aggressively, double down on candidates showing early efficacy, either in solid tumors or specific hematologic settings.
You can see the impact in how R&D budgets are now allocated. According to 2026 disclosures, nearly 60 percent of GSK’s IO spend is now funneled to CD123/CD47 bispecifics and next-gen TCRs. The rest of the pipeline, targets like TIGIT and LAG-3, overrun by “me-too” competition, has been left behind. Every dollar matters, so management is making clear choices. Every bet on a crowded target means less for programs with first- or best-in-class potential. Brutal, but that’s the new environment.
And here’s something specialty pharmacists and payers are already feeling: if GSK does get new IO launches through in 2026, they’ll be narrower, higher-priced, and closely tethered to outcomes-based contracting. Pre-authorization hurdles are getting tighter, and in many cases, GSK’s negotiation with PBMs is what’s shaping these new rules. That’s the legacy of 2025’s PBM economics, a year when IO reimbursement got tougher, fast.
Other Pharmas Take Note: The New Risk-Sharing Benchmarks
What’s happening now? Competitors are paying attention. Mid-cap European pharmas like UCB and Ipsen have already started to echo the GSK approach, no more bloated, headline-grabbing milestones. Instead, staged, data-driven payments. Regional rights sliced more surgically. In practice, this has meant fewer “$1B+” deal headlines in 2026, more tough negotiation over what’s actually worth funding, and when.
Banking analysts call the shift overdue. In 2025, IO deal values typically hit 17x forward revenue as a hypothetical, but actual payouts rarely crossed 25 percent of those totals. The restructurings mean smaller total dollars change hands, but payouts are more certain, and public companies have less risk of shock write-downs when trials fail. Small biotech partners might miss the fantasy payouts, but the market now pays a premium for “money in hand”, especially while biotech capital markets remain tight post-2025.
GSK’s willingness to take its medicine in public has put plenty of pressure on rivals. At this point, any company still touting multi-billion-dollar milestone stacks for lackluster programs looks a little delusional. The dealmaking bar is higher: discipline around trial design, clarity on commercial value, and strict gatekeeping on which deals even see daylight. This is where the lessons of 2025 have landed us.
For ongoing coverage of how these deal structures evolve, and who blinks next, check RxNews.ai for fresh term sheets and fallout. That’s probably where I’ll be looking, too.
